Pharmaceutical

Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma

Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.

Aug 7, 2024 - 04:00
Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma
Antengene received approval from the Malaysian National Pharmaceutical Regulatory Agency for XPOVIO NDA for two multiple myeloma indications.
Read the original article

Tags:

Previous Article

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

Next Article

CVC Capital to pay $925 Million to Mallinckrodt for sale of Therakos Business Unit

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A physician’s Mother’s Day gift: reclaimed time with my children — and for myself

A physician’s Mother’s Day gift: reclaimed time with my...

May 13, 2023

Elahere secures full approval from FDA for types of ovarian cancer

Elahere secures full approval from FDA for types of ova...

Mar 26, 2024

Commercial drug manufacturing companies for the pharmaceutical industry

Commercial drug manufacturing companies for the pharmac...

Sep 22, 2024